🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

217 results for “Merck Sharp and Dohme” Clear

  1. A clinical study of the V540A vaccine in healthy adults (V540A-001)

    Merck Sharp and Dohme

    Human Papilloma virus

    phase 1 other active

    1 trial

  2. A clinical study of the V540C vaccine in healthy adults (V540C-003)

    Merck Sharp and Dohme

    Human Papilloma virus

    phase 1 other active

    1 trial

  3. A clinical trial of MK-1824 in healthy participants (MK-1824-001)

    Merck Sharp and Dohme

    Heart failure with preserved ejection fraction

    phase 1 other active

    1 trial

  4. A clinical trial of MK-3214 taken with different liquids in healthy participants (MK-3214-002)

    Merck Sharp and Dohme

    Hypercholesterolaemia

    phase 1 other active

    1 trial

  5. A clinical trial of MK-4605 in healthy participants (MK-4605-001)

    Merck Sharp and Dohme

    Dementia

    phase 1 other active

    1 trial

  6. A clinical trial of MK-6050 in healthy participants (MK-6050-002)

    Merck Sharp and Dohme

    Hidradenitis suppurativa

    phase 1 other active

    1 trial

  7. A clinical trial of MK-6916 in healthy participants (MK-6916-010)

    Merck Sharp and Dohme

    Acute and Chronic pain

    phase 1 other active

    1 trial

  8. A clinical trial of MK-7228 in adults (MK-7228-002)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

  9. Anti-GD2 ADC M3554 in Advanced Solid Tumors

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  10. Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  11. Effect of Renal Impairment on Enpatoran Pharmacokinetics

    Merck Sharp and Dohme

    Healthy volunteers and patients with renal impairment; Intended indication: autoimmune diseases; systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), as well as dermatomyositis (DM) and polymyositis (PM).

    phase 1 other active

    1 trial

  12. LENVIMA 10 mg hard capsules, LENVIMA 4 mg hard capsules, Bavencio 20 mg/mL concentrate for solution for infusion, LENVIMA 4 mg hard capsules, LENVIMA 10 mg hard capsules, LENVIMA 4 mg hard capsules, LENVIMA 10 mg hard capsules

    Merck Sharp and Dohme

    Central Nervous System Tumors

    phase 1 small molecule active

    1 trial

  13. M9466 Alone or in Combination in Advanced Solid Tumors (DDRiver 501)

    Merck Sharp and Dohme

    Advanced solid tumors

    phase 1 other active

    1 trial

  14. M9466 in Combination with Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

    Merck Sharp and Dohme

    Advanced solid tumors and colorectal cancer

    phase 1 other active

    1 trial

  15. MK-2420 SAD Study

    Merck Sharp and Dohme

    Rheumatoid arthritis

    phase 1 other active

    1 trial

  16. MK-4318 CIDF Target Engagement Study

    Merck Sharp and Dohme

    Pain

    phase 1 other active

    1 trial

  17. MK-4646 Single Ascending Dose Study and DDI in Healthy Participants

    Merck Sharp and Dohme

    HIV infection

    phase 1 other active

    1 trial

  18. MK-7091 Formulations Study in Healthy Adult Participants

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 1 other active

    1 trial

  19. MK-7480 Multiple Ascending Dose Study in Healthy Participants

    Merck Sharp and Dohme

    Non-alcoholic steatohepatitis

    phase 1 other active

    1 trial

  20. Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants

    Merck Sharp and Dohme

    Healthy

    phase 1 other active

    1 trial

  21. Phase 1b safety study of xevinapant, weekly cisplatin, and radiotherapy in participants with unresected LA SCCHN

    Merck Sharp and Dohme

    Locally Advanced Squamous Cell Carcinoma of the Head and Neck

    phase 1 other active

    1 trial

  22. Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

    Merck Sharp and Dohme

    Advanced Pancreatic cancer, Unresectable Glioblastoma and Variants, PD-1-exposed Advanced/Met HNSCC, Advanced/Met HNSCC, Advanced/Met NSCLC, Advance/Met RCC, Advanced/Met Gastric or GEJ adenocarcinoma, Ovarian Cancer. TNBC, Advanced Mesothelioma, Advanced Solid tumors(coformulation)

    phase 1 other active

    1 trial

  23. Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  24. Tuvusertib (M1774) in Participants with Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

    Merck Sharp and Dohme

    Metastatic or Locally Advanced Unresectable Solid Tumors

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources